Abbott Laboratories

ABT is in an early Stage 1 consolidation following a terminal decline, but the mid-July Momentum Breakout above multi-week resistance signals new bullish asymmetry. Despite this breakout, price is extended and at extreme overbought levels, so Dividend Growth strategy prefers waiting for a disciplined pullback into the rising 9 and 21 EMAs or the recent breakout zone before engaging.

• ↑Q1 revenue $11.16B (+3.7%), adjusted EPS $1.15 (+6% YoY)
• ↑Exact Sciences acquisition to contribute ~$3B sales in 2026
• ↓Diagnostics segment sales declined 1.5% due to reduced COVID testing